Results 91 to 100 of about 21,815 (182)

Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma

open access: yesNeoplasia: An International Journal for Oncology Research, 2020
Androgen Receptor (AR) signaling is a critical driver of hormone-dependent prostate cancer and has also been proposed to have biological activity in female hormone-dependent cancers, including type I endometrial carcinoma (EMC).
Christopher S. Koivisto   +14 more
doaj   +1 more source

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives

open access: yes, 2016
Jia Luo,1 Julie N Graff2,3 1Department of Medicine; 2Knight Cancer Institute, Oregon Health & Science University, 3VA Portland Health Care System, Portland, OR, USA Abstract: Prostate cancer claims the lives of more than 25,000 men in the United
Graff JN, Luo J
core  

Which ARPI first in chemotherapy-naïve mCRPC? Enzalutamide versus abiraterone: A nationwide real-world study

open access: yesTherapeutic Advances in Medical Oncology
Background Abiraterone and enzalutamide are widely used androgen receptor pathway inhibitors (ARPIs) for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), but the optimal initial treatment strategy remains uncertain ...
Jin Bong Choi, Yun-Hee Lee, U-Syn Ha
doaj   +1 more source

EP300‐Mediated MTF1‐K218 Lactylation Buffers AR‐Driven Copper Overload to Suppress Cuproptosis in Castration‐Resistant Prostate Cancer

open access: yesAdvanced Science, Volume 13, Issue 61, 3 November 2026.
Androgen receptor (AR) drives copper accumulation in prostate cancer while inducing MTF1 to buffer copper toxicity. EP300‐mediated lactylation of MTF1 at K218 promotes its nuclear translocation and metallothionein expression, sequestering cytosolic copper and preventing mitochondrial cuproptosis.
Kai Li   +21 more
wiley   +1 more source

TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model

open access: yesBMC Cancer, 2019
Background Castrate Resistant Prostate Cancer (CRPC) is an advanced disease resistant to systemic traditional medical or surgical castration, and resistance is primarily attributed to reactivation of AR through multiple mechanisms.
Louie Semaan   +3 more
doaj   +1 more source

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang   +4 more
wiley   +1 more source

Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Graphical overview of targeted protein degradation: mechanisms, molecular determinants, delivery strategies, and therapeutic development. This graphical abstract summarizes the major degradation pathways involved in targeted protein degradation, including the ubiquitin–proteasome system, endocytosis–lysosome pathway, and autophagy‐dependent degradation.
Huaijuan Guo   +8 more
wiley   +1 more source

Antioxidant Programs Are Essential for Enzalutamide-Resistant Prostate Cancer [PDF]

open access: yes
Therapy resistance to second generation androgen receptor (AR) antagonists, such as enzalutamide, is common in patients with advanced prostate cancer (PCa).
Blatt, Eliot Benjamin
core   +1 more source

Risk of seizure in patients with prostate cancer treated with enzalutamide in China: a noninterventional study

open access: yesTherapeutic Advances in Drug Safety
Background: Enzalutamide, approved in China for the treatment of prostate cancer (PC), has been studied for risk of seizure, but there is limited real-world evidence on this risk in China.
Yong Wang   +13 more
doaj   +1 more source

Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review

open access: yesPharmaceuticals
Objective: To review the efficacy and safety of reduced dose compared to standard dose Enzalutamide treatment for patients with castration-resistant prostate cancer (CRPC). Methods: PubMed, Scopus, Web of Science, and Cochrane databases were searched for
Zineddine Belabaci   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy